Last reviewed · How we verify
NCT04199559
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
Phase 1, PHASE2 trial testing Autologous dendritic cells pulsed with antigen in NSCLC in 30 participants. Status unknown.
1 January 2021
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 December 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Autologous dendritic cells pulsed with antigen — full drug profile →
Conditions studied
- NSCLC — all drugs for NSCLC →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 70, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study Arms: Patients receive autologous dendritic cells pulsed with antigen peptides ID on days 15, 29, 43,57,71,99,127and 155, and nivolumab IV over 60 minutes on days 15, 29, 43,57,71,85 99 and 113.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363 -
Dendritic Cell-Based Immunotherapy in Lung Cancer.
Stevens D, Ingels J, Van Lint S, Vandekerckhove B, et al · · 2020 · cited 55× · PMID 33679709 · DOI 10.3389/fimmu.2020.620374 -
A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.
Hannani D, Leplus E, Laurin D, Caulier B, et al · · 2023 · cited 19× · PMID 36768214 · DOI 10.3390/ijms24031897 -
Clinicopathological and Prognostic Significance of Inhibitor of Apoptosis Protein (IAP) Family Members in Lung Cancer: A Meta-Analysis.
Fung S, Knoefel WT, Krieg A. · · 2021 · cited 11× · PMID 34439255 · DOI 10.3390/cancers13164098 -
Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.
Naik A, Lattab B, Qasem H, Decock J. · · 2024 · cited 10× · PMID 38596293 · DOI 10.1016/j.omton.2024.200768 -
Adoptive T Cell Therapy Targeting MAGE-A4.
Chandora K, Chandora A, Saeed A, Cavalcante L. · · 2025 · cited 4× · PMID 39941782 · DOI 10.3390/cancers17030413 -
Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.
Zhu W, Yi Q, Chen Z, Wang J, et al · · 2025 · cited 4× · PMID 39905312 · DOI 10.1186/s10020-025-01079-8 -
Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review.
de Oliveira JB, Silva SB, Fernandes IL, Batah SS, et al · · 2024 · cited 4× · PMID 39308861 · DOI 10.3389/fimmu.2024.1376704
Verify or expand the search:
- PubMed search for NCT04199559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04199559 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 16 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04199559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing